{"id":994830,"date":"2026-08-13T08:36:51","date_gmt":"2026-08-13T12:36:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmatrix-announces-second-quarter-2026-financial-results-and-progress-on-merger\/"},"modified":"2026-08-13T08:36:51","modified_gmt":"2026-08-13T12:36:51","slug":"pulmatrix-announces-second-quarter-2026-financial-results-and-progress-on-merger","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmatrix-announces-second-quarter-2026-financial-results-and-progress-on-merger\/","title":{"rendered":"Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Form S-4 filed related to the announced merger agreement with\u00a0Eos SENOLYTIX<\/i>\n <\/p>\n

\n FRAMINGHAM, Mass.<\/span>, Aug. 13, 2026<\/span> \/PRNewswire\/ — Pulmatrix, Inc.<\/a>\u00a0(“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE\u2122 technology, today announced its second quarter financial results for 2026 and provided a corporate update\u00a0related to the merger agreement with Eos SENOLYTIX announced at the end of the first quarter of 2026.<\/p>\n

\n

\n \"\"\n <\/p>\n<\/p><\/div>\n

Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented, “Our focus in the second quarter and beyond has been to advance steps towards completing the proposed merger with Eos SENOLYTIX, a privately held biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases using the MitoXcel\u2122 platform. To that end, we have filed a Form S-4 in relation to the Merger.”<\/p>\n

\n
\n Proposed Merger with Eos SENOLYTIX<\/i>
\n <\/b>\n <\/p>\n

As previously reported, on March 26, 2026, the Company entered into an agreement (the “Merger Agreement”) and plan of merger (the “Merger”) with Eos SENOLYTIX, Inc. (“Eos”). The proposed Merger is currently anticipated to close in the third quarter of 2026, subject to customary closing conditions. If the proposed Merger is completed, the business of Eos will continue as the business of the combined company.<\/p>\n

In connection with the entry into the Merger Agreement, on March 26, 2026, the Company announced that it entered into a securities purchase agreement with an affiliate of Eos for the issuance and sale in a private placement of its newly designated Series B Convertible Preferred Stock, raising aggregate gross proceeds of $1.0 million.<\/p>\n

Additional information about the Merger Agreement was previously disclosed in a registration statement on Form S-4 (File No. 333-297342) initially filed with the Securities and Exchange Commission (the “SEC”) on July 9, 2026, as amended on August 3, 2026.<\/p>\n

\n Pulmatrix Seeks to Out-license or Monetize its Clinical Assets<\/b>\n <\/p>\n

\n
\n iSPERSE\u2122 Technology<\/i>
\n <\/b>\n <\/p>\n